Biomarin Pharmaceutical vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Biomarin Pharmaceutical Inc (BMRN)

Q3 202623 Jun – 30 Sep 2026

▲4

BioMarin advances Voxzogo, adds Alesta, settles patent, raises guidance

Voxzogo nears full FDA approval and $1B revenue Voxzogo moved toward full FDA approval, with a decision expected February 2027, and approached $1 billion in annual revenue. Positive Phase 3 data in hypochondroplasia supports a filing to expand its label.
Voxzogo is BioMarin's key growth driver, and its regulatory and commercial progress directly boosts investor confidence.
Alesta acquisition adds oral hypophosphatasia therapy BioMarin acquired Alesta, gaining ALE1, a potential first oral treatment for hypophosphatasia. The deal expands the pipeline into a new rare disease area, though ALE1 remains unproven.
The acquisition adds a new pipeline asset and strategic growth opportunity, which can lift investor sentiment.
Patent settlement with Ascendis secures royalties BioMarin settled patent litigation with Ascendis, securing royalties on rival Yuviwel through 2030. This removes legal uncertainty and provides a finite but predictable revenue stream.
The settlement eliminates a legal overhang and adds royalty income, improving financial visibility.
Raised guidance and Amicus synergies improve outlook BioMarin raised its financial guidance, targeted $200 million in annual savings from Amicus synergies, and accelerated deleveraging. An AI enzyme partnership with Profluent adds long-term pipeline potential.
These financial and strategic moves strengthen the company's outlook and support the stock.

September 202631 Aug – 30 Sep 2026

▲4

BioMarin settles patent fight, closes Alesta, and expands VOXZOGO

Patent settlement secures royalties on rival Yuviwel BioMarin settled global patent disputes with Ascendis, winning 20% US and 18% EU/Brazil/South Korea royalties on Yuviwel sales through May 2030. This turns a costly legal fight into a steady income stream and removes uncertainty, lifting the stock.
This is the period's biggest new event, directly adding royalty revenue and removing litigation risk.
Alesta acquisition adds oral hypophosphatasia drug BioMarin completed its purchase of Alesta Therapeutics, adding ALE1, a potential first oral therapy for hypophosphatasia, to its pipeline. This strengthens the rare bone disease portfolio and gives investors a new growth candidate beyond existing drugs.
A new pipeline asset expands future revenue potential and shows management is investing in growth.
VOXZOGO nears $1B, Amicus synergies on track VOXZOGO grew patients 20% quarterly and is expected to hit $1 billion in revenue this year, while Amicus integration targets $200 million in annual cost savings and faster debt reduction. Strong sales plus cost cuts boost profits and cash flow.
This shows the core growth driver and merger savings that directly improve earnings and balance sheet.
VOXZOGO hypochondroplasia data and AI enzyme deal BioMarin reported positive Phase 3 results for VOXZOGO in hypochondroplasia and filed for FDA approval, expanding its label. It also partnered with Profluent to use AI to design new enzyme therapies, adding long-term pipeline potential.
New indication and AI partnership broaden the franchise and future pipeline, supporting the growth story.

Latest31 Aug – 30 Sep 2026

▲4

BioMarin settles patent fight, closes Alesta, and expands VOXZOGO

Patent settlement secures royalties on rival Yuviwel BioMarin settled global patent disputes with Ascendis, winning 20% US and 18% EU/Brazil/South Korea royalties on Yuviwel sales through May 2030. This turns a costly legal fight into a steady income stream and removes uncertainty, lifting the stock.
This is the period's biggest new event, directly adding royalty revenue and removing litigation risk.
Alesta acquisition adds oral hypophosphatasia drug BioMarin completed its purchase of Alesta Therapeutics, adding ALE1, a potential first oral therapy for hypophosphatasia, to its pipeline. This strengthens the rare bone disease portfolio and gives investors a new growth candidate beyond existing drugs.
A new pipeline asset expands future revenue potential and shows management is investing in growth.
VOXZOGO nears $1B, Amicus synergies on track VOXZOGO grew patients 20% quarterly and is expected to hit $1 billion in revenue this year, while Amicus integration targets $200 million in annual cost savings and faster debt reduction. Strong sales plus cost cuts boost profits and cash flow.
This shows the core growth driver and merger savings that directly improve earnings and balance sheet.
VOXZOGO hypochondroplasia data and AI enzyme deal BioMarin reported positive Phase 3 results for VOXZOGO in hypochondroplasia and filed for FDA approval, expanding its label. It also partnered with Profluent to use AI to design new enzyme therapies, adding long-term pipeline potential.
New indication and AI partnership broaden the franchise and future pipeline, supporting the growth story.

July 202623 Jun – 18 Aug 2026

▲4

BioMarin's Voxzogo Expansion, Amicus Deal, and Alesta Buy Drive Growth

Voxzogo Regulatory Progress The FDA accepted BioMarin's application for full approval of Voxzogo, with a decision expected by February 2027. This moves the drug closer to broader use, which could boost sales and reassure investors about the company's growth path.
This is a key regulatory milestone that directly affects future revenue from BioMarin's flagship drug.
Raised Guidance and Faster Deleveraging BioMarin raised its 2025 revenue and earnings guidance and now expects to cut debt faster than planned, thanks to the Amicus acquisition. This signals stronger financial health and growth from new products like Galafold and Pombiliti/Opfolda.
It shows improved financial performance and balance sheet strength, which can lift investor confidence and the stock price.
Alesta Acquisition Adds Oral Therapy BioMarin agreed to buy Alesta Therapeutics for $275 million upfront to gain ALE1, a potential first oral treatment for hypophosphatasia. This expands the pipeline into a new disease area with a convenient pill form, which could drive future growth.
It represents a strategic pipeline expansion that may open a new market and diversify revenue.
Sustained Voxzogo Data in Hypochondroplasia New three-year data showed Voxzogo continued to improve growth in children with hypochondroplasia, and BioMarin plans to file for approval in this new use. This could significantly expand the patient population and sales potential.
It supports label expansion into a larger market, directly impacting future revenue growth.

23 Jun – 18 Aug 2026

▲4

BioMarin's Voxzogo Expansion, Amicus Deal, and Alesta Buy Drive Growth

Voxzogo Regulatory Progress The FDA accepted BioMarin's application for full approval of Voxzogo, with a decision expected by February 2027. This moves the drug closer to broader use, which could boost sales and reassure investors about the company's growth path.
This is a key regulatory milestone that directly affects future revenue from BioMarin's flagship drug.
Raised Guidance and Faster Deleveraging BioMarin raised its 2025 revenue and earnings guidance and now expects to cut debt faster than planned, thanks to the Amicus acquisition. This signals stronger financial health and growth from new products like Galafold and Pombiliti/Opfolda.
It shows improved financial performance and balance sheet strength, which can lift investor confidence and the stock price.
Alesta Acquisition Adds Oral Therapy BioMarin agreed to buy Alesta Therapeutics for $275 million upfront to gain ALE1, a potential first oral treatment for hypophosphatasia. This expands the pipeline into a new disease area with a convenient pill form, which could drive future growth.
It represents a strategic pipeline expansion that may open a new market and diversify revenue.
Sustained Voxzogo Data in Hypochondroplasia New three-year data showed Voxzogo continued to improve growth in children with hypochondroplasia, and BioMarin plans to file for approval in this new use. This could significantly expand the patient population and sales potential.
It supports label expansion into a larger market, directly impacting future revenue growth.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.